Should I buy Taylor Morrison (TMHC) stock or is it too late?
No reliable analyst is bullish on this stock right now. A “reliable” analyst is a firm that, on this sector, hits more than 55% of its targets and beats its sector. None of them sees upside here — which is exactly why this stock is in no JPI selection.
Firm-by-firm track record on Taylor Morrison
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| JP Morgan | 0 % | 0.0 % | 8 | $82 |
| Barclays | 0 % | 0.0 % | 6 | $73 |
| Wedbush | 0 % | 0.0 % | 5 | $85 |
| RBC Capital | 0 % | 0.0 % | 8 | $73 |
| B. Riley Securities | 0 % | 0.0 % | 5 | $36 |
| Credit Suisse | 0 % | 0.0 % | 7 | — |
| Citigroup | 0 % | 0.0 % | 6 | — |
| Deutsche Bank | 0 % | 0.0 % | 6 | — |
✅ Reasons to believe
- The most reliable firm on TMHC, Barclays (0% hit rate, 6 scored calls), targets $73 (call made on July 14, 2026, maturing on July 14, 2027) (—) in its most recent call, and $70 (call made on February 12, 2026, maturing on February 12, 2027) (—) in the one coming due soonest.
⚠️ Reasons to hesitate
- The consensus is not unanimous: of 7 ratings, 7 are neutral.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- Volatile stock: sharp swings — including steep drops — are part of its profile.
- No dividend: your return depends only on price appreciation.
The analyst consensus on TMHC
Median target $73 (—) · 7 ratings · Hold consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Taylor Morrison now?
We won't decide for you. The facts: 0% of analysts rate it a buy, median target $73 (—), and Barclays (most reliable on TMHC, 0%) targets $73. Weigh that against valuation and volatility. This is not personalized advice.
Is it too late to invest in Taylor Morrison?
The stated upside is small: the median target ($73) sits near the price (—) (most reliable on TMHC: Barclays, 0%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Taylor Morrison still worth investing in?
It depends on the gap between the price (—) and its estimated value: analysts target $73 on median (—), with 0% buys (most reliable on TMHC: Barclays, 0%). Cross-check with their real reliability on TMHC and the cautions above. Information, not advice.
What's the main risk in buying TMHC?
The consensus is not unanimous: of 7 ratings, 7 are neutral.
→ Go deeper: the full Taylor Morrison profile (consensus, analyst reliability, price target, performance).